X4 Pharmaceuticals
XFOR
36 hedge funds and large institutions have $25.7M invested in X4 Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 10 closing their positions.
72% more capital invested
Capital invested by funds: $14.9M → $25.7M (+$10.8M)
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
0.07% more ownership
Funds ownership: 0.36% → 0.43% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 40 → 36 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.95M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$872K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.7K |
| 4 |
BlackRock
New York
|
+$58.4K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$53.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$265K |
| 2 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$217K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$169K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$100K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$94K |
XFOR Hedge Fund Activity: Q4 2018 in Review
36 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2018, worth a combined $25.7M — up 72% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XFOR and 6 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 11 added.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $3.95M. The largest seller was Citigroup, cutting an estimated $265K.
- 36 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2018, down from 40 in Q3 2018.
- Funds reported $25.7M of X4 Pharmaceuticals stock for Q4 2018, up 72% quarter-over-quarter.
- 6 funds opened new X4 Pharmaceuticals positions in Q4 2018 and 10 closed out, a net change of -4 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2018 was Cormorant Asset Management, an estimated $3.95M added.
- The largest X4 Pharmaceuticals seller in Q4 2018 was Citigroup, an estimated $265K sold.
Based on aggregated 13F filings for Q4 2018.